SG Americas Securities LLC Buys 2,858 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK)

SG Americas Securities LLC increased its stake in Anika Therapeutics, Inc. (NASDAQ:ANIK) by 43.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,485 shares of the biotechnology company’s stock after purchasing an additional 2,858 shares during the period. SG Americas Securities LLC owned 0.07% of Anika Therapeutics worth $234,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Lazard Asset Management LLC bought a new position in Anika Therapeutics in the 1st quarter worth approximately $180,000. State Board of Administration of Florida Retirement System bought a new position in Anika Therapeutics in the 1st quarter worth approximately $198,000. BNP Paribas Financial Markets raised its position in Anika Therapeutics by 16.9% in the 1st quarter. BNP Paribas Financial Markets now owns 22,240 shares of the biotechnology company’s stock worth $565,000 after purchasing an additional 3,217 shares during the last quarter. American Century Companies Inc. raised its position in Anika Therapeutics by 11.8% in the 2nd quarter. American Century Companies Inc. now owns 23,892 shares of the biotechnology company’s stock worth $605,000 after purchasing an additional 2,518 shares during the last quarter. Finally, Ironwood Investment Management LLC raised its position in Anika Therapeutics by 109.9% in the 2nd quarter. Ironwood Investment Management LLC now owns 28,704 shares of the biotechnology company’s stock worth $727,000 after purchasing an additional 15,032 shares during the last quarter. Institutional investors own 91.53% of the company’s stock.

Anika Therapeutics Stock Performance

ANIK opened at $24.44 on Tuesday. The company has a fifty day moving average price of $25.11 and a two-hundred day moving average price of $25.81. Anika Therapeutics, Inc. has a 52 week low of $18.08 and a 52 week high of $29.11. The firm has a market capitalization of $356.51 million, a PE ratio of -4.66 and a beta of 0.83.

Anika Therapeutics (NASDAQ:ANIK) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.24). Anika Therapeutics had a positive return on equity of 0.94% and a negative net margin of 44.45%. The business had revenue of $41.92 million for the quarter, compared to analyst estimates of $39.90 million. During the same period in the prior year, the firm posted ($0.06) EPS. Equities analysts forecast that Anika Therapeutics, Inc. will post -0.1 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Barrington Research restated an “outperform” rating and issued a $37.00 price objective on shares of Anika Therapeutics in a research report on Friday, August 9th.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.